- Home
- MBRX
as 06-27-2025 4:00pm EST
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 12.9M | IPO Year: | 2016 |
| Target Price: | $5.33 | AVG Volume (30 days): | 5.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.25 - $4.71 | Next Earning Date: | 08-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Moleculin Biotech Inc. News
MBRX Breaking Stock News: Dive into MBRX Ticker-Specific Updates for Smart Investing
Argus Research
4 days ago
Daily – Vickers Top Buyers & Sellers for 06/24/2025
TipRanks
7 days ago
Moleculin Biotech prices 16.08M shares at 37c in public offering
MT Newswires
7 days ago
Top Midday Decliners
MT Newswires
8 days ago
Moleculin Biotech Prices $5.9 Million Offering of Shares, Warrants
GlobeNewswire
8 days ago
Moleculin Announces $5.9 Million Public Offering
GlobeNewswire
10 days ago
Moleculin Participates in Virtual Investor “What This Means” Segment
GlobeNewswire
10 days ago
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML
TipRanks
16 days ago
Moleculin Biotech announces ‘What This Means’ virtual investor segment
Compare MBRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MBRX Moleculin Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.